Replies to post #117832 on NanoViricides Inc. (NNVC)

[loanranger]

How about answering my question?

Which of these four is he saying has been Designed, Synthesized and is now in the Testing stage?


"In the HerpeCide™ program, the Company is currently developing drugs against four different topical indications, namely: (a) skin cream/lotion for the topical treatment of "cold sores" (typically caused by HSV-1); (b) eye drops/gel for the treatment of ocular herpes keratitis (mostly caused by HSV-1, sometimes by HSV-2 primarily in neonates); (c) skin cream/lotion for the treatment of "genital lesions" caused by herpesvirus (typically HSV-2); and (d) skin cream/lotion for the treatment of shingles (caused by HHV-3 also known as VZV i.e the chickenpox virus)."



Where are we now along this path??
1.Design 8 first-round drug candidates.
2.Synthesize the 8 first-round drug candidates.
3.Test the 8 first-round drug candidates.
4.Select the best two approaches.
5.Design the 8 second-round drug candidates.
6.Synthesize the 8 second-round drug candidates.
7.Test the 8 second-round drug candidates.
8.Select the best drug candidate.
9.Produce enough drug to sent for tox testing.


The response:
Re: HerpesCide

#3

Eugene Seymour MD MPH